A Phase II Study to Determine the Efficacy and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With HPV-16 Induced Grade 3 Cervical Intraepithelial Neoplasia
Latest Information Update: 01 Sep 2023
At a glance
- Drugs Vvax 001 (Primary)
- Indications Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Therapeutic Use
- 12 Nov 2020 New trial record